Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593069 | PMC |
http://dx.doi.org/10.3389/fbioe.2022.1016311 | DOI Listing |
Int J Mol Sci
January 2025
Melanoma Institute Australia, Sydney, NSW 2065, Australia.
The field of translational bioinformatics is rapidly evolving, driving the convergence of molecular sciences and computational methods with their applications in industrial and clinical practice [...
View Article and Find Full Text PDFNPJ Digit Med
January 2025
Digital Medicine Society, Boston, MA, USA.
We propose the addition of usability validation to the extended V3 framework, now "V3+", and describe a pragmatic approach to ensuring that sensor-based digital health technologies can be used optimally at scale by diverse users. Alongside the original V3 components (verification; analytical validation; clinical validation), usability validation will ensure user-centricity of digital measurement tools, paving the way for more inclusive, reliable, and trustworthy digital measures within clinical research and clinical care.
View Article and Find Full Text PDFFEBS Open Bio
January 2025
FEBS Open Bio Editorial Office, Cambridge, UK.
Different societal, systemic and personal barriers exist at various stages along a female researcher's career that can potentially undermine their success. The equation for women to reach higher positions in STEM is a multivariable one, and while there has been considerable progress towards addressing some of these compared with the past, current solutions are inadequate and do not address all facets. Here, we asked female winners of the FEBS Open Bio poster prize about their experiences regarding barriers they have faced at the predoctoral and postdoctoral stages, their opinions on how these can be addressed and their advice to new students entering a PhD degree.
View Article and Find Full Text PDFJ Med Chem
January 2025
Experimental Drug Development Centre, Chromos, Agency for Science, Technology and Research, 10 Biopolis Road, #05-01, Singapore 138670.
The discovery of molecular glues has made significant strides, unlocking new avenues for targeted protein degradation as a therapeutic strategy, thereby expanding the scope of drug discovery into territories previously considered undruggable. Pioneering molecules like thalidomide and its derivatives have paved the way for the development of small molecules that can induce specific protein degradation by hijacking the cellular ubiquitin-proteasome system. Recent advancements have focused on expanding the range of E3 ligases and target proteins that can be modulated by molecular glues.
View Article and Find Full Text PDFToxics
December 2024
Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA.
Per- and polyfluoroalkyl substances (PFAS) are nearly ubiquitous and found in rivers, soils, atmosphere, food packaging, clothing, cosmetics, commercial products, homes, drinking water, and humans and other organisms [...
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!